Skip to main content

Consistency May Be a Hobgoblin, But We Appreciate It Anyway

Daniel MacArthur at Genetic Future blogs about an Australian company called Genetic Technologies that appears to be reneging on a promise to allow other screening labs to test for BRCA1 and BRCA2, for which it won exclusive testing rights in Australia and New Zealand five years ago. Earlier this month, MacArthur says, "familial cancer screening laboratories around Australia and New Zealand received letters from the company ordering that they cease offering the tests within seven days. ... The concern, of course, is that this move will grant a complete monopoly to Genetic Technologies as the sole testing facility in the region, driving prices up." MacArthur posits that the move may be an attempt to shore up the company's falling stock price.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.